AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12211491 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 48
Study 9658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy after EMR for elevated type lesions
Number of subjects: 26
Study 9658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy after EMR for depressed type lesions
Number of subjects: 26
Study 9658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional laser therapy for recurring lesions
Number of subjects: 26
Study 7852748 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg daily)
Number of subjects: 18
Study 7852748 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily)
Number of subjects: 18
Study 7852748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2475589 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intensive-induction chemotherapy (arm A) with daunorubicin, vincristine, and cytarabine for remission induction.
Number of subjects: 60
Study 2475589 — intervention group
Group type: COMPARATOR
Intervention: Supportive care and mild cytoreductive chemotherapy (arm B) for palliation of leukemia-associated complications.
Number of subjects: 60
Study 4990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 26
Study 4990 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg ketamine
Number of subjects: 26
Study 4990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of ketamine
Number of subjects: 26
Study 29116954 — intervention group
Group type: EXPERIMENTAL
Intervention: New methodological tool for CAPA identification
Number of subjects: 56
Study 29116954 — intervention group
Group type: COMPARATOR
Intervention: Usual adverse event management tools
Number of subjects: 56
Study 30036394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 21
Study 30036394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (in vitro)
Number of subjects: 21
Study 30036394 — intervention group
Group type: COMPARATOR
Intervention: Belatacept
Number of subjects: 21
Study 27366745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 27366745 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 25560342 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (100 mg PO bid), amoxicillin, and omeprazole
Number of subjects: 120
Study 25560342 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin, amoxicillin, and omeprazole
Number of subjects: 120
Study 23034420 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage, full-mouth, ultrasonic debridement (FMUD)
Number of subjects: 31
Study 19997942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg/day) + Omeprazole (20 mg/day) for 12 weeks
Number of subjects: 64
Study 18418294 — intervention group
Group type: EXPERIMENTAL
Intervention: Terameprocol (90 mg, 2% w/w ointment) administered intravaginally for 7 consecutive days
Number of subjects: 14
Study 18418294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 14
Study 16046202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg preparation
Number of subjects: 36
Study 16046202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 150 mg preparation
Number of subjects: 36
Study 11815344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (preservative-free)
Number of subjects: 86
Study 11815344 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 86
Study 10188144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg daily
Number of subjects: 247
Study 10188144 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg daily
Number of subjects: 247
Study 10188144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 7788827 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 0.03 mg.kg‐1
Number of subjects: 60
Study 7788827 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 0.015 mg.kg‐1 + esmolol 1 mg.kg‐1
Number of subjects: 60
Study 7788827 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 2 mg.kg‐1
Number of subjects: 60
Study 7788827 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study 2146812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin preparation
Number of subjects: 12
Study 2146812 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation consisting of human serum albumin
Number of subjects: 12
Study 672091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers (n=28)
Number of subjects: 58
Study 672091 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (n=30)
Number of subjects: 58
Study 6810682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 38
Study 6810682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30986785 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of stroke symptoms
Number of subjects: 670
Study 30986785 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of self-risk for stroke
Number of subjects: 670
Study 30986785 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender perception of self-risk
Number of subjects: 670
Study 30986785 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for hospital care for stroke-like symptoms
Number of subjects: 670
Study 30986785 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of hospital preference with socioeconomic status
Number of subjects: 670
Study 28840324 — intervention group
Group type: COMPARATOR
Intervention: Mental rehearsal with a pre‐prepared checklist (Group A)
Number of subjects: 16
Study 28840324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal with checklist and virtual models (Group B)
Number of subjects: 16
Study 26595362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg conbercept
Number of subjects: 53
Study 26595362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-mg conbercept
Number of subjects: 53
Study 24974440 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Strength Testing (MMST)
Number of subjects: 30
Study 24974440 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament Testing (MFT)
Number of subjects: 30
Study 22458336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered advance care planning (PC-ACP)
Number of subjects: 313
Study 22458336 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 313
Study 20375967 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone foam dressing (Mepilex Border)
Number of subjects: 32
Study 20375967 — intervention group
Group type: COMPARATOR
Intervention: Adhesive hydrocellular polyurethane foam dressing (Allevyn Adhesive)
Number of subjects: 32
Study 17496674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (first variation)
Number of subjects: 35
Study 17496674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (second variation)
Number of subjects: 35
Study 17496674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (both variations)
Number of subjects: 35
Study 15724760 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SM) adhesive
Number of subjects: 57
Study 15724760 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB) adhesive
Number of subjects: 57
Study 15724760 — intervention group
Group type: EXPERIMENTAL
Intervention: One Coat Bond (OCB) adhesive
Number of subjects: 57
Study 15724760 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 57
Study 15724760 — intervention group
Group type: EXPERIMENTAL
Intervention: All adhesives
Number of subjects: 57
Study 12140623 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.05 mg/kg)
Number of subjects: 28
Study 12140623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9623685 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 27417A (20 mg)
Number of subjects: 12
Study 8124603 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs or novel drug combinations, new therapeutic modalities, or technological improvements of old modalities
Number of subjects: 0
Study 8124603 — intervention group
Group type: COMPARATOR
Intervention: New therapies that represent modest, incremental advances over existing treatment
Number of subjects: 0
Study 2643513 — intervention group
Group type: EXPERIMENTAL
Intervention: D-alpha-tocopheryl acetate (Vitamin E 400 IU/day)
Number of subjects: 24
Study 2643513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 56650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycerol
Number of subjects: 27
Study 56650 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextrose
Number of subjects: 27
Study 31606655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 135
Study 31606655 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital droplet polymerase chain reaction (ddPCR)
Number of subjects: 135
Study 28182498 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE training programs
Number of subjects: 0
Study 28182498 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cognitive performance
Number of subjects: 0
Study 25818564 — intervention group
Group type: EXPERIMENTAL
Intervention: 2WAT
Number of subjects: 20
Study 25818564 — intervention group
Group type: EXPERIMENTAL
Intervention: 4WAT
Number of subjects: 20
Study 25818564 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 20
Study 23835915 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 50
Study 23835915 — intervention group
Group type: COMPARATOR
Intervention: Microscopic approach
Number of subjects: 50
Study 23835915 — intervention group
Group type: COMPARATOR
Intervention: Comparison of synechia presence
Number of subjects: 50
Study 21350204 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission warfarin use
Number of subjects: 1739
Study 19266830 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 35 microg/kg administered intravenously 30 minutes before conclusion of surgery (Group MI)
Number of subjects: 60
Study 19266830 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 35 microg/kg premedication 15 minutes before induction of anesthesia (Group MP)
Number of subjects: 60
Study 19266830 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 15 minutes before induction and 30 minutes before extubation (Group NS)
Number of subjects: 60
Study 17920548 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking co‐stimulatory signals
Number of subjects: 0
Study 17920548 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking monoclonal antibodies
Number of subjects: 0
Study 15564948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (titrated to 2,400 mg daily)
Number of subjects: 41
Study 15564948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15564948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 41
Study 11778528 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone treatment
Number of subjects: 23
Study 11778528 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 23
Study 8861661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 0
Study 8861661 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice and erythromycin (CYP3A inhibitors)
Number of subjects: 0
Study 1293307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily for 2 weeks, then increased to 10 mg daily for 4 weeks if DBP was not < 90 mmHg or decreased by > 10 mmHg from baseline.
Number of subjects: 11
Study 1293307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 11
Study 6538006 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-vinyl GABA (1 g and 2 g daily for 2 weeks each)
Number of subjects: 10
Study 6538006 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (2 weeks)
Number of subjects: 10
Study 31308344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with HDM 300 IR tablets for 52 weeks
Number of subjects: 89
Study 31308344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 29474117 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) techniques training for healthcare providers
Number of subjects: 0
Study 27174596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0
Study 27174596 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus a pan‐PI3K inhibitor
Number of subjects: 0
Study 25566958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia group (n = 86)
Number of subjects: 1044
Study 25566958 — intervention group
Group type: COMPARATOR
Intervention: Non-dementia group (n = 958)
Number of subjects: 1044
Study 23294513 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual stress-management intervention (low-intensity followed by more intensive treatment if needed)
Number of subjects: 300
Study 23294513 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual stress-management intervention
Number of subjects: 300
Study 23294513 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 300
Study 20497879 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐CMC solution (5 mL applied to the operative field after thyroidectomy)
Number of subjects: 74
Study 20497879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HA‐CMC solution)
Number of subjects: 74
Study 18820783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral cardiac denervation
Number of subjects: 50
Study 18820783 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 50
Study 17243084 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity of 45-60 minutes, fat-reduced diet with plenty of fruit, vegetables, whole grain, lean meat, and dairy products, moderate consumption of calorie-containing beverages.
Number of subjects: 0
Study 17243084 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing daily physical activity and regular exercise during the weight maintenance phase.
Number of subjects: 0
Study 17243084 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of starchy carbohydrates with protein from lean meat and dairy products.
Number of subjects: 0
Study 17243084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy calcium consumption.
Number of subjects: 0
Study 12811359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 186 mg daily
Number of subjects: 1042
Study 12811359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (various doses: 0, 50, 150, 300, and 600 mg)
Number of subjects: 1042
Study 12811359 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (various doses)
Number of subjects: 1042
Study 11028738 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated impulse stimulator
Number of subjects: 70
Study 11028738 — intervention group
Group type: COMPARATOR
Intervention: Inactivated impulse stimulator (non-stimulation group)
Number of subjects: 70
Study 8707473 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tasks (sequence task and novel task)
Number of subjects: 0
Study 8707473 — intervention group
Group type: COMPARATOR
Intervention: Oddball task
Number of subjects: 0
Study 1644129 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal command with opposing spring-like load (negative linear position feedback)
Number of subjects: 0
Study 1644129 — intervention group
Group type: EXPERIMENTAL
Intervention: Coactivation command with assisting load (positive position feedback)
Number of subjects: 0
Study 1644129 — intervention group
Group type: COMPARATOR
Intervention: No load condition after training with opposing or assisting loads
Number of subjects: 0
Study 6548428 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide alcohol flushing (CPAF)
Number of subjects: 0
Study 6548428 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm ischaemia
Number of subjects: 0
Study 6548428 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of plasma levels of 6-oxo-PGF1 alpha and TXB2
Number of subjects: 0
Study 30448936 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (14 kcal kg-1 body weight weekly)
Number of subjects: 49
Study 30448936 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic exercise (8 kcal kg-1 body weight weekly)
Number of subjects: 49
Study 29287665 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 1056
Study 29287665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 1056
Study 29287665 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a telephone quitline
Number of subjects: 1056
Study 29287665 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting program
Number of subjects: 1056
Study 29287665 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1056
Study 27437769 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-gene risk score based on expression of ABCC4, ADRBK2, KLHL23, PDS5A, UHRF1, ZNF551
Number of subjects: 96
Study 27437769 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score from merged public datasets
Number of subjects: 96
Study 25183042 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 654
Study 25183042 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 654
Study 21939613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg/d
Number of subjects: 221
Study 21939613 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 2 mg/d
Number of subjects: 221
Study 21939613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 20643486 — intervention group
Group type: EXPERIMENTAL
Intervention: Left rTMS
Number of subjects: 48
Study 20643486 — intervention group
Group type: EXPERIMENTAL
Intervention: Right rTMS
Number of subjects: 48
Study 20643486 — intervention group
Group type: COMPARATOR
Intervention: Left sham
Number of subjects: 48
Study 20643486 — intervention group
Group type: COMPARATOR
Intervention: Right sham
Number of subjects: 48
Study 17764782 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 75 microg subcutaneously
Number of subjects: 40
Study 17764782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of 0.9% normal saline solution subcutaneously)
Number of subjects: 40
Study 17764782 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (1 ampule of 50% dextrose intravenously and carbohydrates orally) + Placebo
Number of subjects: 40
Study 17764782 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (1 ampule of 50% dextrose intravenously and carbohydrates orally) + Octreotide
Number of subjects: 40
Study 15809460 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer testing
Number of subjects: 810
Study 15809460 — intervention group
Group type: COMPARATOR
Intervention: Repeated ultrasonography
Number of subjects: 810
Study 12748877 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies in epileptic patients
Number of subjects: 74
Study 12748877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies in epileptic patients
Number of subjects: 74
Study 12748877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid decarboxylase antibodies in epileptic patients
Number of subjects: 74
Study 12748877 — intervention group
Group type: COMPARATOR
Intervention: Anticardiolipin antibodies in seizure-free patients
Number of subjects: 74
Study 12748877 — intervention group
Group type: COMPARATOR
Intervention: Glutamic acid decarboxylase antibodies in seizure-free patients
Number of subjects: 74
Study 12748877 — intervention group
Group type: COMPARATOR
Intervention: Antinuclear antibodies in well-controlled epilepsy
Number of subjects: 74
Study 10234587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) measurements at multiple bone sites including calcaneus, distal third and ultradistal radius, proximal third phalanx, metacarpal, capitate, patella, and posterior process of the thoracic spine.
Number of subjects: 79
Study 10234587 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal radius and calcaneus measurements.
Number of subjects: 79
Study 10234587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment at two sites (calcaneus and distal radius).
Number of subjects: 79
Study 7914238 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg)
Number of subjects: 32
Study 7914238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3551850 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate
Number of subjects: 0
Study 3551850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29608976 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle stretching
Number of subjects: 10
Study 29608976 — intervention group
Group type: COMPARATOR
Intervention: Control (at rest)
Number of subjects: 10
Study 27716091 — intervention group
Group type: EXPERIMENTAL
Intervention: DWL‐FWSC (Durable Wall Lining - Full Wall Surface Coverage)
Number of subjects: 146
Study 27716091 — intervention group
Group type: EXPERIMENTAL
Intervention: DWL‐RWSC (Durable Wall Lining - Reduced Wall Surface Coverage)
Number of subjects: 146
Study 27716091 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 146
Study 26232169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/high carbohydrate meal
Number of subjects: 30
Study 26232169 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA)
Number of subjects: 30
Study 26232169 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 30
Study 26232169 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated fatty acids (PUFA)
Number of subjects: 30